Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

• Status: Completed
• Trial end date: 2004-06-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and interferon alfa in treating patients with chronic myelogenous leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Cyclophosphamide; Cytarabine; Etoposide; Etoposide phosphate; Interferon-alpha; Interferons; Methotrexate; Mitoxantrone; Sargramostim

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of chronic myelogenous leukemia in blast crisis

• Bone marrow blasts at least 20% OR

• Bone marrow blasts plus promyelocytes at least 50%

• Ineligible for higher priority protocols

PATIENT CHARACTERISTICS:

Age:

• 16 and over

Performance status:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL

Renal:

• Creatinine less than 2.0 mg/dL

Cardiovascular:

• LVEF greater than 50% by MUGA scan or echocardiogram

Other:

• HIV negative

• Not pregnant

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• Prior therapy for blast crisis allowed